Trade Gilead Sciences - GILD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.15 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Gilead Sciences Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 80.79 |
Open* | 80.78 |
1-Year Change* | 35.51% |
Day's Range* | 80.78 - 81.98 |
52 wk Range | 57.17-89.74 |
Average Volume (10 days) | 6.23M |
Average Volume (3 months) | 127.95M |
Market Cap | 101.52B |
P/E Ratio | 22.34 |
Shares Outstanding | 1.25B |
Revenue | 27.28B |
EPS | 3.64 |
Dividend (Yield %) | 3.69049 |
Beta | 0.40 |
Next Earnings Date | Apr 26, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 30, 2023 | 81.05 | -0.17 | -0.21% | 81.22 | 82.08 | 80.58 |
Mar 29, 2023 | 80.93 | 0.10 | 0.12% | 80.83 | 81.89 | 80.23 |
Mar 28, 2023 | 80.83 | 1.40 | 1.76% | 79.43 | 81.04 | 78.35 |
Mar 27, 2023 | 78.94 | -1.04 | -1.30% | 79.98 | 80.90 | 78.61 |
Mar 24, 2023 | 79.94 | 1.68 | 2.15% | 78.26 | 80.31 | 78.12 |
Mar 23, 2023 | 78.05 | 0.35 | 0.45% | 77.70 | 78.86 | 75.94 |
Mar 22, 2023 | 77.88 | -0.26 | -0.33% | 78.14 | 79.30 | 77.59 |
Mar 21, 2023 | 78.29 | -0.99 | -1.25% | 79.28 | 79.96 | 78.29 |
Mar 20, 2023 | 78.82 | 2.26 | 2.95% | 76.56 | 79.59 | 76.14 |
Mar 17, 2023 | 77.23 | -2.28 | -2.87% | 79.51 | 79.78 | 76.46 |
Mar 16, 2023 | 78.98 | 0.19 | 0.24% | 78.79 | 79.88 | 77.74 |
Mar 15, 2023 | 78.98 | -0.65 | -0.82% | 79.63 | 79.82 | 78.03 |
Mar 14, 2023 | 78.62 | -0.12 | -0.15% | 78.74 | 79.83 | 78.24 |
Mar 13, 2023 | 79.28 | -0.26 | -0.33% | 79.54 | 81.19 | 76.94 |
Mar 10, 2023 | 79.00 | 0.48 | 0.61% | 78.52 | 80.24 | 77.61 |
Mar 9, 2023 | 78.90 | -0.83 | -1.04% | 79.73 | 80.58 | 78.22 |
Mar 8, 2023 | 79.73 | -0.36 | -0.45% | 80.09 | 80.68 | 79.48 |
Mar 7, 2023 | 79.79 | -0.94 | -1.16% | 80.73 | 81.23 | 79.79 |
Mar 6, 2023 | 81.04 | 0.27 | 0.33% | 80.77 | 81.25 | 80.35 |
Mar 3, 2023 | 80.57 | 1.14 | 1.44% | 79.43 | 81.09 | 79.03 |
Gilead Sciences Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 27281 | 27305 | 24689 | 22449 | 22127 |
Revenue | 27281 | 27305 | 24689 | 22449 | 22127 |
Cost of Revenue, Total | 5657 | 6601 | 4572 | 4675 | 4853 |
Gross Profit | 21624 | 20704 | 20117 | 17774 | 17274 |
Total Operating Expense | 19951 | 17387 | 20618 | 18162 | 13927 |
Selling/General/Admin. Expenses, Total | 5673 | 5246 | 5151 | 4381 | 4056 |
Research & Development | 5921 | 5540 | 10895 | 8934 | 4846 |
Unusual Expense (Income) | 2700 | 172 | 172 | ||
Operating Income | 7330 | 9918 | 4071 | 4287 | 8200 |
Interest Income (Expense), Net Non-Operating | -1592 | -1611 | -2684 | 227 | -964 |
Other, Net | 76 | -29 | 282 | 646 | 563 |
Net Income Before Taxes | 5814 | 8278 | 1669 | 5160 | 7799 |
Net Income After Taxes | 4566 | 6201 | 89 | 5364 | 5464 |
Minority Interest | 26 | 24 | 34 | 22 | -5 |
Net Income Before Extra. Items | 4592 | 6225 | 123 | 5386 | 5459 |
Net Income | 4592 | 6225 | 123 | 5386 | 5455 |
Income Available to Common Excl. Extra. Items | 4592 | 6225 | 123 | 5386 | 5459 |
Income Available to Common Incl. Extra. Items | 4592 | 6225 | 123 | 5386 | 5455 |
Dilution Adjustment | |||||
Diluted Net Income | 4592 | 6225 | 123 | 5386 | 5455 |
Diluted Weighted Average Shares | 1262 | 1262 | 1263 | 1277 | 1308 |
Diluted EPS Excluding Extraordinary Items | 3.63867 | 4.93265 | 0.09739 | 4.2177 | 4.17355 |
Dividends per Share - Common Stock Primary Issue | 2.92 | 2.84 | 2.72 | 2.52 | 2.28 |
Diluted Normalized EPS | 5.31889 | 4.93265 | 0.09739 | 4.30525 | 4.26568 |
Total Extraordinary Items | -4 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 7389 | 7042 | 6260 | 6590 | 7244 |
Revenue | 7389 | 7042 | 6260 | 6590 | 7244 |
Cost of Revenue, Total | 1396 | 1395 | 1442 | 1424 | 2627 |
Gross Profit | 5993 | 5647 | 4818 | 5166 | 4617 |
Total Operating Expense | 5122 | 4205 | 4231 | 6393 | 6304 |
Selling/General/Admin. Expenses, Total | 2020 | 1213 | 1357 | 1083 | 1650 |
Research & Development | 1706 | 1597 | 1432 | 1186 | 2027 |
Unusual Expense (Income) | 0 | 0 | 0 | 2700 | |
Operating Income | 2267 | 2837 | 2029 | 197 | 940 |
Interest Income (Expense), Net Non-Operating | -287 | -426 | -545 | -334 | -181 |
Other, Net | 51 | 21 | 19 | -15 | |
Net Income Before Taxes | 2031 | 2432 | 1503 | -152 | 759 |
Net Income After Taxes | 1633 | 1786 | 1135 | 12 | 376 |
Minority Interest | 7 | 3 | 9 | 7 | 6 |
Net Income Before Extra. Items | 1640 | 1789 | 1144 | 19 | 382 |
Net Income | 1640 | 1789 | 1144 | 19 | 382 |
Income Available to Common Excl. Extra. Items | 1640 | 1789 | 1144 | 19 | 382 |
Income Available to Common Incl. Extra. Items | 1640 | 1789 | 1144 | 19 | 382 |
Diluted Net Income | 1640 | 1789 | 1144 | 19 | 382 |
Diluted Weighted Average Shares | 1265 | 1261 | 1260 | 1262 | 1262 |
Diluted EPS Excluding Extraordinary Items | 1.29644 | 1.41872 | 0.90794 | 0.01506 | 0.30269 |
Dividends per Share - Common Stock Primary Issue | 0.73 | 0.73 | 0.73 | 0.73 | 0.71 |
Diluted Normalized EPS | 1.29644 | 1.41872 | 0.90794 | 1.40571 | 0.30269 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 14772 | 15996 | 30296 | 35836 | 31823 |
Cash and Short Term Investments | 6520 | 7408 | 24352 | 30089 | 25510 |
Cash & Equivalents | 5338 | 5997 | 11631 | 17940 | 7588 |
Short Term Investments | 1182 | 1411 | 12721 | 12149 | 17922 |
Total Receivables, Net | 4493 | 4892 | 3582 | 3327 | 3851 |
Accounts Receivable - Trade, Net | 4493 | 4892 | 3582 | 3327 | 3851 |
Total Inventory | 1618 | 1683 | 922 | 814 | 801 |
Prepaid Expenses | 2141 | 2013 | 1403 | 1533 | 1649 |
Total Assets | 67952 | 68407 | 61627 | 63675 | 70283 |
Property/Plant/Equipment, Total - Net | 5663 | 5613 | 5170 | 4006 | 3295 |
Goodwill, Net | 8332 | 8108 | 4117 | 4117 | 4159 |
Intangibles, Net | 33455 | 33126 | 13786 | 15738 | 17100 |
Long Term Investments | 1309 | 502 | 1488 | 1423 | 11194 |
Other Long Term Assets, Total | 4421 | 5062 | 6770 | 2555 | 2712 |
Total Current Liabilities | 11610 | 11397 | 9759 | 10605 | 11635 |
Accounts Payable | 705 | 844 | 713 | 790 | 814 |
Accrued Expenses | 7600 | 7198 | 6254 | 6876 | 7271 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1516 | 2757 | 2499 | 2748 | 2747 |
Other Current Liabilities, Total | 1789 | 598 | 293 | 191 | 803 |
Total Liabilities | 46883 | 50205 | 39102 | 42288 | 49841 |
Total Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
Long Term Debt | 25179 | 28645 | 22094 | 24574 | 30795 |
Minority Interest | -5 | 19 | 125 | 147 | 59 |
Other Liabilities, Total | 5743 | 10144 | 7124 | 6962 | 7352 |
Total Equity | 21069 | 18202 | 22525 | 21387 | 20442 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 1 | 1 | 1 | 1 | 1 |
Additional Paid-In Capital | 4661 | 3880 | 3051 | 2282 | 1264 |
Retained Earnings (Accumulated Deficit) | 16324 | 14381 | 19388 | 19024 | 19012 |
Unrealized Gain (Loss) | -4 | 2 | 1 | -52 | 194 |
Other Equity, Total | 87 | -62 | 84 | 132 | -29 |
Total Liabilities & Shareholders’ Equity | 67952 | 68407 | 61627 | 63675 | 70283 |
Total Common Shares Outstanding | 1254 | 1254 | 1266 | 1282 | 1308 |
Other Current Assets, Total | 37 | 73 | 12 | ||
Property/Plant/Equipment, Total - Gross | 7556 | 7281 | 6592 | 5197 | 4289 |
Accumulated Depreciation, Total | -1893 | -1668 | -1422 | -1191 | -994 |
Deferred Income Tax | 4356 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 12629 | 14772 | 13991 | 13925 | 13278 |
Cash and Short Term Investments | 5325 | 6520 | 5738 | 6525 | 5666 |
Cash & Equivalents | 4296 | 5338 | 4362 | 4893 | 4065 |
Short Term Investments | 1029 | 1182 | 1376 | 1632 | 1601 |
Total Receivables, Net | 3787 | 4493 | 4566 | 4149 | 3925 |
Accounts Receivable - Trade, Net | 3787 | 4493 | 4566 | 4149 | 3925 |
Total Inventory | 1482 | 1618 | 1676 | 1772 | 1779 |
Prepaid Expenses | 2035 | 2141 | 2011 | 1479 | 1908 |
Total Assets | 63080 | 67952 | 67098 | 67984 | 67492 |
Property/Plant/Equipment, Total - Net | 5253 | 5121 | 5037 | 4996 | 4990 |
Goodwill, Net | 8314 | 8332 | 8332 | 8334 | 8334 |
Intangibles, Net | 30331 | 33455 | 33900 | 34341 | 34781 |
Long Term Investments | 1427 | 1309 | 1099 | 836 | 579 |
Other Long Term Assets, Total | 5126 | 4963 | 4739 | 5552 | 5530 |
Total Current Liabilities | 8558 | 11610 | 10245 | 10214 | 9705 |
Accounts Payable | 583 | 705 | 585 | 608 | 570 |
Accrued Expenses | 6483 | 7600 | 6702 | 6906 | 6661 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1025 | 1516 | 2511 | 2261 | 2259 |
Other Current Liabilities, Total | 467 | 1789 | 447 | 439 | 215 |
Total Liabilities | 43153 | 46883 | 45628 | 48281 | 48540 |
Total Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
Long Term Debt | 25183 | 25179 | 25175 | 27914 | 27907 |
Deferred Income Tax | 3687 | 4356 | 4603 | 4374 | 4464 |
Minority Interest | -12 | -5 | 1 | 7 | 12 |
Other Liabilities, Total | 5737 | 5743 | 5604 | 5772 | 6452 |
Total Equity | 19927 | 21069 | 21470 | 19703 | 18952 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 1 | 1 | 1 | 1 | 1 |
Additional Paid-In Capital | 4867 | 4661 | 4492 | 4271 | 4092 |
Retained Earnings (Accumulated Deficit) | 14986 | 16324 | 16903 | 15392 | 14821 |
Unrealized Gain (Loss) | -23 | -4 | -1 | -1 | 0 |
Other Equity, Total | 96 | 87 | 75 | 40 | 38 |
Total Liabilities & Shareholders’ Equity | 63080 | 67952 | 67098 | 67984 | 67492 |
Total Common Shares Outstanding | 1255 | 1254 | 1255 | 1254 | 1254 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | 6201 | 89 | 5364 | 5460 | 4644 |
Cash From Operating Activities | 11384 | 8168 | 9144 | 8400 | 11898 |
Cash From Operating Activities | 329 | 288 | 255 | 226 | 233 |
Amortization | 1721 | 1192 | 1149 | 1203 | 1053 |
Deferred Taxes | -116 | -214 | -2098 | 289 | -82 |
Non-Cash Items | 2760 | 8451 | 5272 | 2161 | 942 |
Cash Taxes Paid | 2509 | 2639 | 1793 | 3198 | 3342 |
Cash Interest Paid | 979 | 951 | 982 | 1070 | 1038 |
Changes in Working Capital | 489 | -1638 | -798 | -939 | 5108 |
Cash From Investing Activities | -3131 | -14615 | -7817 | 14355 | -16069 |
Capital Expenditures | -579 | -650 | -825 | -924 | -590 |
Other Investing Cash Flow Items, Total | -2552 | -13965 | -6992 | 15279 | -15479 |
Cash From Financing Activities | -8877 | 770 | -7634 | -12318 | 3393 |
Financing Cash Flow Items | -145 | -138 | -122 | -486 | -330 |
Total Cash Dividends Paid | -3605 | -3449 | -3222 | -2971 | -2731 |
Issuance (Retirement) of Stock, Net | -377 | -1327 | -1540 | -2611 | -720 |
Issuance (Retirement) of Debt, Net | -4750 | 5684 | -2750 | -6250 | 7174 |
Foreign Exchange Effects | -35 | 43 | -2 | -85 | 137 |
Net Change in Cash | -659 | -5634 | -6309 | 10352 | -641 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 12 | 6201 | 5825 | 3239 | 1722 |
Cash From Operating Activities | 1840 | 11384 | 8179 | 4926 | 2610 |
Cash From Operating Activities | 80 | 329 | 239 | 157 | 78 |
Amortization | 445 | 1721 | 1276 | 835 | 395 |
Deferred Taxes | -651 | -116 | 243 | 3 | 71 |
Non-Cash Items | 3116 | 2760 | 1921 | 1564 | 753 |
Changes in Working Capital | -1162 | 489 | -1325 | -872 | -409 |
Cash From Investing Activities | -1070 | -3131 | -2853 | -2619 | -2042 |
Capital Expenditures | -247 | -579 | -423 | -284 | -165 |
Other Investing Cash Flow Items, Total | -823 | -2552 | -2430 | -2335 | -1877 |
Cash From Financing Activities | -1794 | -8877 | -6935 | -3408 | -2477 |
Financing Cash Flow Items | -91 | -145 | -134 | -95 | -89 |
Total Cash Dividends Paid | -945 | -3605 | -2711 | -1811 | -917 |
Issuance (Retirement) of Stock, Net | -258 | -377 | -340 | -252 | -221 |
Issuance (Retirement) of Debt, Net | -500 | -4750 | -3750 | -1250 | -1250 |
Foreign Exchange Effects | -18 | -35 | -26 | -3 | -23 |
Net Change in Cash | -1042 | -659 | -1635 | -1104 | -1932 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9207 | 111403199 | -68465 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.0154 | 87609319 | 3078449 | 2022-12-31 | LOW |
Capital World Investors | Investment Advisor | 5.5167 | 68892972 | 11130228 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7198 | 58941373 | -298977 | 2022-12-31 | LOW |
Capital Research Global Investors | Investment Advisor | 4.3724 | 54602952 | 727482 | 2022-12-31 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 2.8735 | 35885152 | -484100 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9097 | 23848477 | 244886 | 2022-12-31 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.307 | 16322394 | 84245 | 2023-02-28 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.2224 | 15265179 | 12533445 | 2022-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 1.1098 | 13859234 | 761084 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0402 | 12989939 | -106202 | 2022-12-31 | LOW |
Parnassus Investments, LLC | Investment Advisor | 0.9659 | 12062537 | 295282 | 2022-12-31 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8558 | 10686823 | -393685 | 2022-12-31 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7794 | 9733453 | -126327 | 2022-12-31 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.7762 | 9693019 | -93438 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7521 | 9391729 | -99918 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.7369 | 9202568 | -820000 | 2022-12-31 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7185 | 8972729 | -116113 | 2022-12-31 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.6911 | 8630001 | -344541 | 2022-12-31 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6779 | 8465274 | -377056 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the NASDAQ-100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com